Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.7 ILa | +3.19% | +3.19% | +177.14% |
04-29 | Top Premarket Gainers | MT |
03-21 | XTL Biopharmaceuticals Ltd. announced that it expects to receive $1.5 million in funding | CI |
Sales 2021 | - | Sales 2022 | - | Capitalization | 6.36M 2.39B 508M |
---|---|---|---|---|---|
Net income 2021 | - 0 0 | Net income 2022 | -1M -375M -79.77M | EV / Sales 2021 | - |
Net cash position 2021 | 6.13M 2.3B 489M | Net cash position 2022 | 3.72M 1.4B 297M | EV / Sales 2022 | - |
P/E ratio 2021 |
39.2
x | P/E ratio 2022 |
-4.72
x | Employees | 5 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 93.3% |
1 day | +3.19% | ||
1 week | +3.19% | ||
Current month | -3.00% | ||
1 month | -3.00% | ||
3 months | +177.14% | ||
6 months | +203.12% | ||
Current year | +177.14% |
Managers | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 29/12/14 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 31/12/98 |
Doron Turgeman
CHM | Chairman | 56 | 29/12/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 29/12/14 |
Director/Board Member | 57 | 28/01/20 | |
Director/Board Member | 53 | 31/03/17 |
Date | Price | Change | Volume |
---|---|---|---|
01/05/24 | 9.7 | +3.19% | 4,376,023 |
30/04/24 | 9.4 | +3.30% | 3,164,550 |
25/04/24 | 9.1 | -3.19% | 533,855 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 01, 2024 at 03:24 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+177.14% | 13.72M | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- XTLB Stock